-- American Society of Hematology (ASH) Meeting -- Numerous VELCADE
abstracts are expected to be featured at the ASH meeting in December
2007. These abstracts may include data from two large, randomized
Phase III trials in patients with newly diagnosed MM. Data may also be
presented on additional VELCADE based combinations in front-line MM and
Non-Hodgkin's Lymphoma (NHL).
Clinical Pipeline Highlights
In addition to VELCADE, the Company continues to advance ten novel molecules in the areas of cancer and inflammatory diseases. Recent progress included the following:
-- MLN0002 - The Company completed enrollment in the bridging trials
designed to evaluate the safety, tolerability, pharmacokinetics and
pharmacodynamics of this novel antibody to the target alpha 4 beta 7,
derived from a new commercially scalable cell line. The Company is
tracking toward pivotal trials with MLN0002 in ulcerative colitis and
-- MLN3897 - The Company is on track to announce top-line results for this
novel CCR1 inhibitor by year end from a 191-patient Phase II proof-of-
concept trial in rheumatoid arthritis.
-- MLN4924 - In October 2007, the Company presented data on this
Millennium-discovered molecule and target at the European Organization
for Research and Treatment of Cancer (EORTC) meeting. Data for this
inhibitor of the Nedd8-activating enzyme showed the molecule
significantly inhibited tumor growth in xenograft models for colorectal
cancer and several types of lymphoma. MLN4924 is expected to enter
Phase I trials in early 2008.
Conference Call and Presentation Reminder
Dr. Dunsire and members of the Millennium leadership team will present
additional details on these results this m
|SOURCE Millennium Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved